Yachoui Ralph, Kreidy Mazen, Parker Brian J
Department of Rheumatology, Marshfield Clinic, Marshfield, Wisconsin, USA; Current affiliation: Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Department of Pulmonary/Critical care, Marshfield Clinic, Marshfield, Wisconsin, USA.
Clin Med Res. 2017 Jun;15(1-2):37-40. doi: 10.3121/cmr.2017.1352.
Sternocostoclavicular hyperostosis (SCCH) is an infrequent chronic inflammatory disorder of the axial skeleton of unknown origin. SCCH goes often unrecognized due to a low level of awareness for the disorder. It typically presents with relapsing and remitting pain in the shoulder, neck, and anterior chest wall area with occasional swelling and tenderness of the sternoclavicular area. The diagnosis is confirmed radiologically by sclerosis and hyperostosis of the sternoclavicular joints. There have been several reports in which intravenous bisphosphonates and tumor necrosis factor-inhibitors have shown reasonable efficacy in the treatment of this disorder. We report a patient with a long history of SCCH in whom pamidronate 60 mg intravenously every 3 months for 3 years failed to reduce symptom severity and improve radiologic findings.
胸锁关节骨质增生症(SCCH)是一种罕见的起源不明的轴向骨骼慢性炎症性疾病。由于对该疾病的认识不足,SCCH常常未被识别。它通常表现为肩部、颈部和前胸壁区域反复出现的疼痛,伴有胸锁关节偶尔的肿胀和压痛。通过胸锁关节的硬化和骨质增生在影像学上得以确诊。有几份报告显示静脉注射双膦酸盐和肿瘤坏死因子抑制剂在治疗该疾病方面具有合理的疗效。我们报告了一名有长期SCCH病史的患者,每3个月静脉注射60毫克帕米膦酸,持续3年,但未能减轻症状严重程度和改善影像学表现。